EW - Edwards Lifesciences Corp Stock Analysis

Edwards Lifesciences Corp (EW) is a publicly traded company listed on the Large. It operates in the Medical Devices industry, part of the broader Healthcare sector. The company has a market capitalization of 47.44B, generates annual revenue of 6.30B, and reports net income of 1.08B. As of the latest data, the stock is trading at 82.39 USD.

From a valuation and risk perspective, the stock presents the following profile: The stock is trading at a high valuation compared to the market average, suggesting investor optimism or growth expectations. The PEG ratio is within a normal range, suggesting the stock is fairly priced for its expected growth. The company has very low leverage, which may indicate conservative financial management or underutilization of debt. This stock does not currently pay a dividend. The stock has average market volatility, aligning with general market movement.

Analyst recommendation stands at Buy (4.02), indicating current market sentiment. Institutional ownership is reported at 90.59%, reflecting confidence from large investors. Over the last 12 months, the stock has shown a performance of 5.63%, trading within a 52-week range of 72.30 - 87.89.

EW - Edwards Lifesciences Corp

82.39
Analyst Consensus
Buy 4.02
EW – Analyst Rating Summary
Analyst Pie Chart
  • Strong Buy: 12
  • Buy: 20
  • Hold: 11
  • Sell: 0
  • Strong Sell: 0
  • Total Analysts:  43

Last update: 2026-05-19 04:35:07
Index: S&P 500 P/E: 44.76 EPS (ttm): 1.84 Insider Own: 1.38% Shs Outstand: 577.00M Perf Week: 6.76%
Market Cap: 47.44B Forward P/E: 24.44 EPS next Y: 3.37 Insider Trans: -2.94% Shs Float: 567.83M Perf Month: 1.73%
Income(ttm): 1.08B PEG: 1.76 EPS next Q: 0.74 Inst Own: 90.59% Short Float: 1.86% Perf Quarter: 5.02%
Revenue(ttm): 6.30B P/S: 7.53 EPS this Y: 17.58% Inst Trans: 1.39% Short Ratio: 2.13 Perf Half Y: -4.32%
Book/sh: 17.90 P/B: 4.60 EPS next Y: 11.99% ROA: 8.17% Short Interest: 10.54M Perf Year: 5.63%
Cash/sh: 6.38 P/C: 12.92 EPS next 5Y: 13.90% ROE: 10.52% 52W Range: 72.30 - 87.89 Perf YTD: -3.35%
Dividend Est.: - P/FCF: 43.54 EPS past 3/5Y: -9.46% 6.79% ROIC: 9.77% 52W High: 87.89 -6.26% Beta: 0.87
Dividend TTM: - Quick Ratio: 3.63 Sales past 3/5Y: 4.08% 6.70% Gross Margin: 77.97% 52W Low: 72.30 13.96% Perf 5Y: -8.53%
Dividend Ex-Date: - Current Ratio: 4.42 EPS Y/Y TTM: 22.90% Oper. Margin: 27.73% RSI (14): 53.16 Volatility: 3.07% 3.05%
Employees: 16000 Debt/Eq: 0.07 Sales Y/Y TTM: 13.81% Profit Margin: 17.06% Recom: 1.59 Target Price: 97.91
Option/Short: Yes / Yes LT Debt/Eq: 0.07 EPS Q/Q: 5.52% Payout: 0.00% Rel Volume: 0.84 Prev Close: 81.38
Sales Surprise: 3.24% EPS Surprise: 6.98% Sales Q/Q: 16.70% Earnings: Apr 23 AMC Avg Volume: 4.94M Price: 82.39
SMA20: 0.78% SMA50: 1.00% SMA200: 1.41% Undervalued: 18.84%
Volume: 4,136,719 Change: 1.24%
Graham's revised valuation formula
Discounted cash flow (DCF) model
Margin of safety

About Edwards Lifesciences Corp

Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It operates through the following geographical segments: United States, Europe, Japan, and Rest of World. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

Attention! Trading on the stock market involves financial risks and is not suitable for everyone. The www.stocks-expert.com does not provide financial market trading services; it is for informational purposes only and is not responsible for the consequences of your trading decisions or the operation of the software. Before starting to trade in any markets, make sure you understand the risks associated with trading and that you have a sufficient level of training.

Copyright © 2024 - 2026 www.stocks-expert.com All Rights Reserved.